Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Lehto Group Plc: Net sales EUR 721.5 million, up 20.7%. Operating profit EUR 37.2 million, or 5.2% of net sales

Lehto Group PlcFinancial statement bulletin 1 January - 31 December 201812 February 2019 at 7:30 a.m.Net sales EUR 721.5 million, up 20.7%. Operating profit EUR 37.2 million, or 5.2% of net sales  This report has been prepared in accordance with the IAS 34 standard. The company complies with half-yearly reporting according to the Finnish Securities Markets Act. The financial statement bulletin is unaudited. Figures in brackets refer to the corresponding period of the previous year, unless otherwise stated. Summary 2018 Group 1-12/2018 1-12/2017 10-12/2018 10-

Moberg Pharma AB Year-end report 2018

MAJOR TRANSFORMATION OF THE COMPANY AFTER A STRONG YEAR This year-end report 2018 is made public in advance due to the transaction press release announced earlier today regarding the divestment of Moberg Pharma’s OTC-business.PERIOD (FULL YEAR 2018) · Net revenue SEK 439.0 million (439.0, current portfolio 369.2). Current portfolio growth of 16%* · EBITDA SEK 101.7 million (89.4) including, and SEK 96.7 million (76.4) excluding, capital gains** · EBITDA margin 23% (20) · EBITDA for commercial operations SEK 123.1 million (106.0) · Operating profit (EBIT) SEK 64.8 million

Moberg Pharma divests its OTC-business for USD 155 million and secures new funding for MOB-015 in transformational transaction

STOCKHOLM, February 12th, 2019. Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) (OMX: MOB) today announces that it has entered into agreement with a holding company owned by RoundTable Healthcare Partners and Signet Healthcare Partners (the “Purchaser”) to divest MPJ OTC AB and Moberg Pharma North America LLC, which at closing will hold Moberg Pharma’s entire OTC-business, for a cash consideration of USD 155 million (equivalent of SEK 1,431 million[1] ) adjusted for working capital, resulting in a capital gain of approximately SEK 500 million and

Lucara 2018 Year End Results to be Released Thursday, February 21, 2019

Vancouver, February 11, 2019 /CNW/ - (LUC – TSX, LUC – BSE, LUC – Nasdaq Stockholm) Lucara Diamond Corp. (“Lucara” or the “Company”) announces that it will be publishing its 2018 Year End Results on Thursday, February 21, 2019, after the market close in North America. The Company will host a conference call and webcast to discuss the results on Friday, February 22, 2019, at 7:00 a.m. Pacific, 10:00 a.m. Eastern, 3:00 p.m. UK, 4:00 p.m. CET. CONFERENCE CALL:Please call in 10 minutes before the conference call starts and stay on the line (an operator will be available to assist you).

Impairment of book values of goodwill in Eniro AB and report for the fourth quarter and the full year 2018

At its meeting today, the Board of Directors of Eniro AB has resolved to conduct impairment of the book values of goodwill totaling approximately SEK -565 million. The non-cash flow impairment is charged to earnings in the fourth quarter of 2018. Today, Eniro also publishes its report for the fourth quarter of 2018 and the full year 2018. Eniro's operating income for the fourth quarter amounts to SEK -565 million, which includes impairment of the book values of goodwill of SEK -565 million. The impairment has no cash flow effect. Testing of the value of all of the Group’s intangible

Tethys Oil 2018 reserves development – 2P reserve replacement ratio 177 percent

Tethys Oil’s net working interest Reserves in Blocks 3&4 Oman as per 31 December 2018 amount to 25,357 thousand barrels of oil (“mbo”) of proven and probable Reserves (2P). The 2P reserve replacement ratio amounts to 177 percent. In addition, Tethys Oil's net working interest resources oil base in Oman amounts to 12,533 mbo of 2C Contingent Resources. The Company’s 2018 and 2017 year-end Reserves reports were audited by ERC Equipoise Limited (“ERCE”) as independent qualified Reserves evaluator.Development of Reserves, Blocks 3&4 (Audited)mbo 1P 2P

Tethys Oil announces 2019 investments and production guidance

· 2019 investments: MUSD 50-55 · 2019 production: annual average of 12,000-13,000 bopdInvestments Under current market conditions and production assumptions, Tethys Oil expects its 2019 investments for the company’s existing operations on Blocks 3&4 and Block 49 in Oman to amount to MUSD 50-55. Focus of the work program in Blocks 3&4 is continued development and appraisal drilling, upgrading of production facilities and other infrastructure, new seismic acquisition and drilling of exploration wells. Focus on Block 49 is to continue the exploration programme. The new seismic data

Ericsson and Intel jointly develop next-generation software defined infrastructure for the 5G era

· Ericsson and Intel are teaming up to develop the next-generation hardware management platform · The joint development will provide a new level of cloudlike agility, transparency and efficiency required for Network Functions Virtualization (NFV), distributed cloud, and 5G · The companies will align development efforts of Ericsson SDI Manager software and Intel® Rack Scale Design (Intel® RSD) and extend these solutions with advanced management capabilitiesEricsson (NASDAQ: ERIC) and Intel Corporation have begun a multi-year collaboration to align ongoing development efforts in

Starbreeze sells back ”System Shock 3” publishing rights to OtherSide Entertainment

STOCKHOLM, SWEDEN (February 11, 2019) – Starbreeze and OtherSide Entertainment have mutually agreed to sell back the publishing rights to OtherSide Entertainment for “System Shock 3”. Starbreeze expects to be fully reimbursed for costs the company has had in connection with development of the game.  Starbreeze acquired the publishing rights for “System Shock 3” in 2017 and has since then partly financed the development of the game. The title owner OtherSide Entertainment and Starbreeze have now reached an agreement whereby Starbreeze returns the publishing rights for the game to

VALMET Oyj: ACQUISITION OF OWN SHARES 11.02.2019

Valmet Oyj NOTIFICATION 11.02.2019 at 18:30 VALMET Oyj: ACQUISITION OF OWN SHARES 11.02.2019 Date 11.02.2019Exchange transaction OstoShare class VALMTAmount 23,000Average price/share 21.4296 EURHighest price/share 21.7400 EURLowest price/share 20.7600 EURTotal price 492,880.80 EUR The shares held by Valmet Oyj on 11.02.2019: VALMT 270,706 On behalf of Valmet Oyj Skandinaviska Enskilda Banken AB (Publ) Antti Salakka Janne Tiihonen For more information, please contact:Tuomas

Clarification – UAE statements on launching Brighter’s diabetes service Actiste.

During Arab Health 2019, January 28-31, MOHAP (UAE Ministry of Health and Prevention) made an official statement on Brighter’s diabetes service Actiste  in a press release. In the press release, MOHAP states that the Ministry launches Actiste in the United Arab Emirates along with Brighter as part of the Ministry’s keenness to offer UAE residents a modern and effective healthcare system with the highest rates of quality. The announcement in full can be reached via the following link:http://www.mohap.gov.ae/en/MediaCenter/News/Pages/2030.aspx Based on these

Moberg Pharma and Bayer sign exclusive license agreement for MOB-015 in Europe

STOCKHOLM, February 11th, 2019, Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Bayer for commercialization of MOB-015 in Europe. Under the agreement, Moberg Pharma is eligible to receive up to EUR 50 million contingent on development and commercial success, as well as supply fees including royalties.Moberg Pharma has entered into a license agreement granting the Consumer Health division of Bayer exclusive European rights to MOB-015, a new topical treatment of onychomycosis based on Moberg’s patented proprietary formulation of terbinafine. Bayer will be marketing,

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 11.02.2019

Fiskars Corporation  NOTIFICATION 11.02.2019 at 18:30 EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 11.02.2019 Date 11.02.2019Exchange transaction BuyShare class FSKRSAmount       1 500Average price/share 19.5433 EUR  Highest price/share 19.7000 EUR Lowest price/share 19.4600 EUR Total price 29,314.95  EUR  The shares held by Fiskars Corporation on 11.02.2019: FSKRS 341,560  On behalf of Fiskars Corporation Skandinaviska Enskilda Banken AB (Publ) Antti Salakka   Janne Tiihonen

Change in Citycon’s Corporate Management Committee

CITYCON OYJ   Stock Exchange Release   11 February 2019 at 18:15 hrsTom Lisiecki, Citycon’s Chief Development Officer and member of the Corporate Management Committee has decided to leave the company to pursue new opportunities outside the company. At the same time he will step down from Citycon´s Corporate Management Committee. The company thanks Tom Lisiecki for his contribution. Espoo, 11 February 2019 For further information, please contact: Mikko PohjalaIR and Communications DirectorTel. +358 40 838 0709mikko.pohjala@citycon.com   Citycon is a leading owner,

STOREBRAND ASA: Storebrand strengthens private equity position through acquisition of Cubera

Storebrand Asset Management has entered into an agreement to acquire Cubera Private Equity [Cubera]. Cubera is a Nordic firm offering investors exposure to Nordic private equity primarily through the secondary market. The firm is a leading player within Nordic private equity and has around NOK 9 billion under management, mainly from international investors. - The transaction strengthens our offering to institutional asset management clients. Storebrand is today the only provider in Norway that includes private equity in its defined contribution portfolios, says Group CEO Odd Arild

BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805

· ABBV-0805 is being evaluated as a potential disease modifying treatment for Parkinson’s Disease Stockholm, Sweden, February 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805. This is a requirement to start clinical trials in the U.S. ABBV-0805, previously named BAN0805, is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. The

Ossur Hf : Transactions in relation to share buyback program

Announcement no. 09/2019 11 February 2019  Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 30 June 2019. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital.

CXENSE ASA – Approval and publication of the prospectus for the rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG OR SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. As previously announced, Cxense ASA (the "Company") will carry out a fully underwritten rights issue (the "Rights Issue") of 12,857,142 new shares in the Company (the "Offer Shares") at a subscription price of NOK 7, raising

Biohit Oyj: Managers' Transactions

BIOHIT Oyj           MANAGERS’ TRANSACTIONS                               11 FEBRUARY 2019  05.45 P.M.Biohit Oyj: Managers' Transactions  Biohit Plc - Managers' transactions - Söderström____________________________________________ Person subject to the notification requirementName: Söderström, DanielaPosition: Other senior managerIssuer: Biohit PlcLEI: 74370089ATTSNBXJVT29 Notification type: INITIAL NOTIFICATIONReference number: 74370089ATTSNBXJVT29_20190211164318_4____________________________________________ Transaction date: 2019-02-06Instrument type: SHAREISIN: FI0009005482Nature of

New European sites in Immunovia’s PanFAM-1, the largest ever prospective multicenter clinical study for early detection of pancreatic cancer

New centers in Sweden and Spain broaden sample ethnic and racial diversity in drive to validate IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer.LUND, SWEDEN ― Immunovia AB today announced that two additional sites, Umeå University Hospital in Sweden and Catalan Institute of Oncology (ICO Hospitalet) – Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, are now part of PanFAM-1, the largest ever prospective study looking at early diagnosis in high-risk individuals with Familial Pancreatic Cancer (FPC). Designed to validate Immunovia ́s

Nomination Committee’s proposal for Board of Directors and Chairman of Gränges AB (publ)

The Nomination Committee of Gränges AB (publ) proposes that the Board members Anders G. Carlberg, Carina Andersson, Mats Backman, Peter Carlsson, Katarina Lindström, Hans Porat and Ragnhild Wiborg will be re-elected at the Annual General Meeting 2019. Anders G. Carlberg is proposed to be re-elected as Chairman of the Board. Gränges’ Nomination Committee before the Annual General Meeting 2019 consists of representatives of the company's three largest shareholders and Gränges’ Chairman of the Board. Prior to the Annual General Meeting 2019, Gränges’ Nomination Committee has the following

ADDvise enters into an agreement to acquire Sonar Oy

ADDvise Group AB (publ) (”ADDvise”) has today entered into an agreement with the shareholders of the Finnish company Sonar Oy (“Sonar”) regarding the acquisition of all shares in Sonar. The closing is expected to take place on March 1st, 2019 (the “Acquisition”). The signing of the Letter of Intent regarding the Acquisition was made public in a press release on December 12th, 2018. · The purchase price amounts to MEUR 3.2 (corresponding to MSEK 33.6) and is based on a cash and debt free basis and will be paid in cash. · An earn-out of a maximum of MEUR 1.1 (corresponding to MSEK 11.

Scandi Standard – Fourth quarter presentation

Scandi Standard will publish its report for the fourth quarter 2018 on Wednesday, 20 February 2019 at 07.30 CET. Conference call at 08.3o CETThe Company will host a conference call for the financial community at 08.30 CET the same day.The conference call will be hosted by Leif Bergvall Hansen, CEO and Anders Hägg, CFO. Dial in numbers: Sweden: 010 884 80 16UK: 020 3936 2999USA: 1 845 709 8568All other locations: +44 20 3936 2999 Participant Access Code: 31 46 39 The presentation used in the conference call will be published at http://www.scandistandard.com prior to

There are no items matching the current filter
There are no more items matching the current filter
Back to top